Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Mesothelioma, Malignant × Immune Checkpoint Inhibitors × 1 year × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 20 Carcinoma, Hepatocellular 11 Neoplasms 7 Melanoma 7 Neoplasm Metastasis 6 Triple Negative Breast Neoplasms 5 Stomach Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Colonic Neoplasms 5 Nasopharyngeal Carcinoma 4 Colorectal Neoplasms 4 Small Cell Lung Carcinoma 3 Recurrence 3 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Renal Cell 3 Solid Cancers 2 Skin Neoplasms 2 Prostatic Neoplasms 2 Pathologic Complete Response 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Gastric / Gastroesophageal Junction Adenocarcinoma 2 Esophageal Squamous Cell Carcinoma 2 EBV-associated Tumors 2 Breast Neoplasms 2 Bites and Stings 2

Interventions

Cisplatin 15 Pemetrexed 12 pembrolizumab 8 Nivolumab 8 Carboplatin 7 Ipilimumab 5 Cyclophosphamide 5 Platinum 4 1,2-diaminocyclohexaneplatinum II citrate 4 Gemcitabine 3 Drug Therapy 3 tremelimumab 2 fludarabine 2 durvalumab 2 atezolizumab 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiation 2 Photochemotherapy 2 Methotrexate 2 Interleukin-2 2 Chemotherapy, Adjuvant 2 sargramostim 1 olaparib 1 niraparib 1 nintedanib 1 methoxyamine 1 lenvatinib 1 enzalutamide 1 decitabine and cedazuridine drug combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡